Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itraconazole - Mayne Pharma

Next Previous
Drug Profile

Itraconazole - Mayne Pharma

Alternative Names: Itragerm; Itraisdin; Lozanoc; Mytra; SUBA; SUBA®-itraconazole; Subacap; Tolsura

Latest Information Update: 28 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mayne Pharma Group
  • Developer INHIBITOR Therapeutics; Mayne Pharma Group
  • Class Antiasthmatics; Antifungals; Antineoplastics; Azoles; Chlorobenzenes; Dioxoles; Piperazines; Small molecules; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P-450 enzyme system inhibitors; Hedgehog cell signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Basal cell cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Mycoses

Highest Development Phases

  • Marketed Mycoses
  • Phase II Prostate cancer
  • Preclinical Lung cancer
  • Discontinued Basal cell cancer

Most Recent Events

  • 22 Aug 2024 INHIBITOR Therapeutics announced the intention to submit IND to the US FDA for their review and guidance by the end of Q1 2025 for basal cell carcinoma
  • 02 May 2024 Discontinued - Phase-II for Basal cell cancer in USA (PO)
  • 19 Dec 2023 Efficacy and safety data from a phase IIb SCORING trial in Basal cell cancer released by Inhibitor Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top